66-Gene Panel for Ulcerative Colitis Treatment Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating ulcerative colitis (UC) are limited by the unclear role of tumor necrosis factor-alpha (TNFα) in its pathogenesis and the need for effective gene markers to predict treatment response and disease management.
Innovation Solution
Identification of a panel of 66 genes with modified expression levels in UC patients, which serve as biomarkers for diagnosing UC and predicting treatment efficacy, using a method involving gene expression profiling and the use of agents like siRNAs, shRNAs, and antibodies to modulate gene activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microarray analysis is used to analyze gene expression in UC patients, then comprehensive gene expression profiling can be obtained, but the complexity of analysis and interpretation increases
Solution Approach 1:
The patent extracts and focuses on a specific panel of 66 genes from the complete microarray data that are most relevant to UC pathogenesis and treatment response. This selective extraction simplifies the analysis while maintaining diagnostic and prognostic accuracy, resolving the contradiction between comprehensive profiling and analysis complexity.
Solution Approach 2:
The patent segments the complex gene expression data into distinct functional categories (inflammatory response, cell adhesion, apoptosis, etc.) based on the 66 selected genes. This segmentation allows for more manageable and interpretable analysis while preserving the comprehensive information needed for accurate diagnosis and treatment prediction.
2Measurement precision
If a panel of 66 genes is used to predict treatment response, then early prediction accuracy is improved, but the complexity of implementing the test increases
Solution Approach 1:
The 66-gene panel serves multiple functions: it can predict treatment response to anti-TNF therapy, diagnose UC, monitor disease activity, and identify patients who may benefit from alternative therapies. This multi-functionality justifies the implementation complexity by providing comprehensive clinical utility from a single test.
Solution Approach 2:
The patent enables preliminary prediction of treatment response before initiating therapy, allowing clinicians to select the most appropriate treatment strategy in advance. This preliminary action prevents wasted resources on ineffective treatments and improves patient outcomes by establishing the correct therapy before disease progression.
3Reliability
If infliximab therapy is administered to UC patients, then clinical response and remission are achieved in many patients, but the cost and potential side effects increase
Solution Approach 1:
The 66-gene expression profile provides feedback on treatment likelihood before therapy initiation, allowing clinicians to identify patients who are most likely to respond to infliximab. This feedback mechanism ensures that expensive immunosuppressive therapy is reserved for patients who will benefit, reducing unnecessary exposure to side effects and costs.
Solution Approach 2:
The patent performs preliminary identification of treatment responders using the 66-gene panel before administering infliximab. This preliminary screening action prevents unnecessary treatment in non-responders, avoiding the costs and side effects associated with ineffective immunosuppressive therapy while ensuring that true responders receive the beneficial treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gene panel allows for early prediction of treatment response and disease management by identifying specific gene expression patterns, enabling targeted therapeutic interventions and improving clinical outcomes in UC patients.
Implementation Method 1
SiRNAs and shRNAs both work via the RNAi pathway and have been successfully used to suppress the expression of genes
Implementation Method 2
Gene expression can be modulated in several different ways, including by the use of siRNAs, shRNAs, antisense molecules and DNAzymes
Implementation Method 3
DNAzymes are catalytic DNA molecules that cleave single-stranded RNA. They are highly selective for the target RNA sequence and as such can be used to down-regulate specific genes through targeting of the messenger RNA
Implementation Method 4
The therapeutic effect of infliximab on the induction and maintenance of clinical remission in Crohn's disease patients
Data Source
AI summary
A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.